VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 62,700 shares, an increase of 22.2% from the May 31st total of 51,300 shares. Based on an average daily trading volume, of 92,100 shares, the short-interest ratio is currently 0.7 days. Currently, 0.5% of the company’s shares are sold short.
VYNE Therapeutics Stock Down 2.5 %
Shares of NASDAQ VYNE opened at $1.92 on Tuesday. The business has a fifty day simple moving average of $2.42 and a two-hundred day simple moving average of $2.35. The firm has a market cap of $27.90 million, a PE ratio of -0.35 and a beta of 1.33. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $6.79.
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. VYNE Therapeutics had a negative net margin of 6,874.47% and a negative return on equity of 56.75%. On average, research analysts expect that VYNE Therapeutics will post -0.77 earnings per share for the current year.
Analyst Upgrades and Downgrades
View Our Latest Report on VYNE Therapeutics
Institutional Trading of VYNE Therapeutics
Several hedge funds have recently modified their holdings of VYNE. Virtu Financial LLC purchased a new position in VYNE Therapeutics in the first quarter worth $50,000. Parkman Healthcare Partners LLC acquired a new stake in shares of VYNE Therapeutics during the fourth quarter worth $1,623,000. Finally, Eventide Asset Management LLC purchased a new stake in shares of VYNE Therapeutics during the fourth quarter valued at $3,249,000. 83.78% of the stock is owned by hedge funds and other institutional investors.
About VYNE Therapeutics
VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
Further Reading
- Five stocks we like better than VYNE Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Compound Interest and Why It Matters When Investing
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Insider Trades May Not Tell You What You Think
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.